The physical interaction between the T cell receptor (TCR) and its cognate antigen causes T cells to activate and participate in the immune response. Understanding this physical interaction is important in predicting TCR binding to a target epitope, as well as potential cross-reactivity. Here, we propose a way of collecting informative features of the binding interface from homology models of T cell receptor-peptide-major histocompatibility complex (TCR-pMHC) complexes.
The information collected from these structures is sufficient to discriminate binding from non-binding TCR-pMHC pairs in multiple independent datasets. The classifier is limited by the number of crystal structures available for the homology modelling and by the size of the training set. However, the classifier shows comparable performance to sequence-based classifiers requiring much larger training sets.
A Novel Treatment for Ewing’s Sarcoma: Chimeric Antigen Receptor–T Cell Therapy
Ewing’s sarcoma (EWS) is a malignant and aggressive tumor type that predominantly occurs in children and adolescents. Traditional treatments such as surgery, radiotherapy and chemotherapy, while successful in the early disease stages, are ineffective in patients with metastases and relapses who often have poor prognosis. Therefore, new treatments for EWS are needed to improve patient’s outcomes.
Chimeric antigen receptor (CAR)-T cells therapy, a novel adoptive immunotherapy, has been developing over the past few decades, and is increasingly popular in researches and treatments of various cancers. CAR-T cell therapy has been approved by the Food and Drug Administration (FDA) for the treatment of leukemia and lymphoma. Recently, this therapeutic approach has been employed for solid tumors including EWS. In this review, we summarize the safety, specificity and clinical transformation of the treatment targets of EWS, and point out the directions for further research.
Autologous Transplant versus Chimeric Antigen Receptor T–cell Therapy for Relapsed DLBCL in Partial Remission
The relative efficacy of autologous hematopoietic cell transplant (auto-HCT) versus chimeric antigen receptor T-cell (CAR-T) therapy in diffuse large B-cell lymphoma (DLBCL) patients who achieve a partial remission (PR) after salvage chemotherapy is not known. Using the Center for International Blood & Marrow Transplant Research registry database, we identified adult DLBCL patients who received either an auto-HCT (2013-2019) or CAR-T treatment with axicabtagene ciloleucel while in a PR by CT or PET scan.
We compared the clinical outcomes between the two cohorts using univariable and multivariable regression models after adjustment for relevant baseline and clinical factors. In the univariable analysis, the 2-year progression-free survival and the rate of 100-day non-relapse mortality (4% vs. 2% ; p=0.3) were not different between the 2 cohorts but consolidation with auto-HCT was associated with a lower rate of relapse/progression (40% vs. 53% ; p=0.05) and a superior overall survival (OS) at 2-years.
In the multivariable regression analysis, treatment with auto-HCT was associated with a significantly lower risk of relapse/progression rate (HR=1.49; p=0.01) and a superior OS (HR=1.63; p=0.008). In patients with DLBCL in a PR after salvage therapy, treatment with auto-HCT was associated with a lower incidence of relapse and a superior OS compared with CAR-T. These data support the role of auto-HCT as the standard-of-care in transplant-eligible patients with relapsed DLBCL in PR after salvage therapy.
Distinct single-component adjuvants steer human DC-mediated T–cell polarization via Toll-like receptor signaling toward a potent antiviral immune response
The COVID-19 pandemic highlights the importance of efficient and safe vaccine development. Vaccine adjuvants are essential to boost and tailor the immune response to the corresponding pathogen. To allow for an educated selection, we assessed the effect of different adjuvants on human monocyte-derived dendritic cells (DCs) and their ability to polarize innate and adaptive immune responses. In contrast to commonly used adjuvants, such as aluminum hydroxide, Toll-like receptor (TLR) agonists induced robust phenotypic and functional DC maturation.
In a DC-lymphocyte coculture system, we investigated the ensuing immune reactions. While monophosphoryl lipid A synthetic, a TLR4 ligand, induced checkpoint inhibitors indicative for immune exhaustion, the TLR7/8 agonist Resiquimod (R848) induced prominent type-1 interferon and interleukin 6 responses and robust CTL, B-cell, and NK-cell proliferation, which is particularly suited for antiviral immune responses.
Indeed, we could confirm that the cytokine profile induced by lipid-complexed RNA was almost identical to the pattern induced by R848. Although this awaits further investigation, our results suggest that their efficacy involves the highly efficient antiviral response pattern stimulated by the RNAs’ TLR7/8 activation.
CNS relapse of acute lymphocytic leukaemia is difficult to treat. Durable remissions of relapsed or refractory B-cell acute lymphocytic leukaemia have been observed following treatment with CD19-directed chimeric antigen receptor (CAR) T cells; however, most trials have excluded patients with active CNS disease. We aimed to assess the safety and activity of CAR T-cell therapy in patients with a history of CNS relapsed or refractory B-cell acute lymphocytic leukaemia.
In this post-hoc analysis, we included 195 patients (aged 1-29 years; 110 [56%] male and 85 [44%] female) with relapsed or refractory CD19-positive acute lymphocytic leukaemia or lymphocytic lymphoma from five clinical trials (Pedi CART19, 13BT022, ENSIGN, ELIANA, and 16CT022) done at the Children’s Hospital of Philadelphia (Philadelphia, PA, USA), in which participants received CD19-directed CAR T-cell therapy between April 17, 2012, and April 16, 2019.
The trials required control of CNS disease at enrolment and infusion and excluded treatment in the setting of acute neurological toxic effects (>grade 1 in severity) or parenchymal lesions deemed to increase the risk of neurotoxicity.The recently licensed COVID-19 vaccines, BNT162b and mRNA-1273, are both based on single-stranded RNA.
Long-term Cell Tracer 580 (Green) sample |
|||
| P710GS | 101Bio | 0.1 ml | EUR 199 |
Long-term Cell Tracer 580 (Yellow) sample |
|||
| P710YS | 101Bio | 0.1 ml | EUR 199 |
CFDA SE Cell Tracer Kit |
|||
| K1023-1 | ApexBio | 1 kit | EUR 96 |
|
Description: Cell Biology|Cell Proliferation & Toxicity |
|||
FluoGreen Tracer, Stains Cell Nuclei and Cytoplasm |
|||
| MBS555420-01mL | MyBiosource | 0.1mL | EUR 435 |
FluoGreen Tracer, Stains Cell Nuclei and Cytoplasm |
|||
| MBS555420-5x01mL | MyBiosource | 5x0.1mL | EUR 1815 |
CFDA, SE Cell Proliferation and Tracer Assay Kit |
|||
| CA1200 | Solarbio Life Science |
|
|
CFDA SE cell proliferation and tracer detection kit |
|||
| ETF0051 | EnoGene | 2000 assays | EUR 300 |
CFDA SE cell prolifeRation and tracer detection kit |
|||
| MBS8579509-2000Assays | MyBiosource | 2000Assays | EUR 400 |
CFDA SE cell prolifeRation and tracer detection kit |
|||
| MBS8579509-5x2000Assays | MyBiosource | 5x2000Assays | EUR 1810 |
FluoGreen Tracer |
|||
| SF41000 | Neuromics | 100 ul | EUR 292.05 |
Tau tracer 1 |
|||
| HY-134879 | MedChemExpress | Get quote | Ask for price |
|
Description: Tau tracer 1 is a Tau tracer used for imaging Tau protein aggregates. Tau tracer 1 can be used to diagnose neurodegenerative diseases[1]. |
|||
Tau tracer 2 |
|||
| HY-134880 | MedChemExpress | 10 mg | EUR 216.45 |
|
Description: Tau tracer 2 (Pl-2620) is a Tau tracer used for imaging Tau protein aggregates. Tau tracer 2 can be used to diagnose neurodegenerative diseases[1]. |
|||
Tau tracer 1 |
|||
| MBS5800094-5mg | MyBiosource | 5(mg | EUR 915 |
Tau tracer 1 |
|||
| MBS5800094-5x5mg | MyBiosource | 5x5(mg | EUR 3970 |
Tau tracer 2 |
|||
| MBS5798041-50mg | MyBiosource | 50(mg | EUR 960 |
Tau tracer 2 |
|||
| MBS5798041-5x50mg | MyBiosource | 5x50(mg | EUR 4180 |
Tau tracer 2 |
|||
| T37051-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: Tau tracer 2 |
|||
Tau tracer 2 |
|||
| T37051-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: Tau tracer 2 |
|||
Tau tracer 2 |
|||
| T37051-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: Tau tracer 2 |
|||
Tau tracer 2 |
|||
| T37051-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: Tau tracer 2 |
|||
Tau tracer 2 |
|||
| T37051-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: Tau tracer 2 |
|||
Tau tracer 1 |
|||
| T39660-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: Tau tracer 1 |
|||
Tau tracer 1 |
|||
| T39660-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: Tau tracer 1 |
|||
Tau tracer 1 |
|||
| T39660-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: Tau tracer 1 |
|||
Tau tracer 1 |
|||
| T39660-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: Tau tracer 1 |
|||
Tau tracer 1 |
|||
| T39660-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: Tau tracer 1 |
|||
JAK2 JH2 Tracer |
|||
| HY-102055 | MedChemExpress | 50mg | EUR 2705.67 |
|
Description: JAK2 JH2 Tracer (Tracer 5) is a fluorescent probe for JAK2 JH2 domain, with a Kd of value 0.2 μM[1][2]. |
|||
JAK2 JH2 Tracer |
|||
| MBS3844504-10mg | MyBiosource | 10mg | EUR 855 |
JAK2 JH2 Tracer |
|||
| MBS3844504-1mg | MyBiosource | 1mg | EUR 225 |
JAK2 JH2 Tracer |
|||
| MBS3844504-50mg | MyBiosource | 50mg | EUR 2450 |
JAK2 JH2 Tracer |
|||
| MBS3844504-5mg | MyBiosource | 5mg | EUR 525 |
JAK2 JH2 Tracer |
|||
| MBS3844504-5x50mg | MyBiosource | 5x50mg | EUR 11020 |
JAK2 JH2 Tracer |
|||
| MBS5755856-50mg | MyBiosource | 50mg | EUR 2840 |
JAK2 JH2 Tracer |
|||
| MBS5755856-5x50mg | MyBiosource | 5x50mg | EUR 12620 |
JAK2 JH2 Tracer |
|||
| T19017-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: JAK2 JH2 Tracer |
|||
JAK2 JH2 Tracer |
|||
| T19017-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: JAK2 JH2 Tracer |
|||
JAK2 JH2 Tracer |
|||
| T19017-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: JAK2 JH2 Tracer |
|||
JAK2 JH2 Tracer |
|||
| T19017-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: JAK2 JH2 Tracer |
|||
JAK2 JH2 Tracer |
|||
| T19017-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: JAK2 JH2 Tracer |
|||
CytoFixâ„¢ BCECF, AM *Optimized for long term cellular pH tracking* |
|||
| 21200-1mg | AAT Bioquest | 1 mg | EUR 318 |
|
Description: Intracellular pH plays an important modulating role in many cellular events, including cell growth, calcium regulation, enzymatic activity, receptor-mediated signal transduction, ion transport, endocytosis, chemotaxis, cell adhesion and other cellular processes. |
|||
ROS tracer precursor |
|||
| HY-126712 | MedChemExpress | Get quote | Ask for price |
|
Description: ROS tracer precursor is the precursor of [18F]ROStrace for the synthesis of ROStrace, which can be used for disease diagnosis[1]. |
|||
ROS tracer precursor |
|||
| MBS5772039-5mg | MyBiosource | 5mg | EUR 915 |
ROS tracer precursor |
|||
| MBS5772039-5x5mg | MyBiosource | 5x5mg | EUR 3970 |
ROS tracer precursor |
|||
| T19550-10mg | TargetMol Chemicals | 10mg | Ask for price |
|
Description: ROS tracer precursor |
|||
ROS tracer precursor |
|||
| T19550-1g | TargetMol Chemicals | 1g | Ask for price |
|
Description: ROS tracer precursor |
|||
ROS tracer precursor |
|||
| T19550-1mg | TargetMol Chemicals | 1mg | Ask for price |
|
Description: ROS tracer precursor |
|||
ROS tracer precursor |
|||
| T19550-50mg | TargetMol Chemicals | 50mg | Ask for price |
|
Description: ROS tracer precursor |
|||
ROS tracer precursor |
|||
| T19550-5mg | TargetMol Chemicals | 5mg | Ask for price |
|
Description: ROS tracer precursor |
|||
BSA tracer Ultra Small |
|||
| 200.033 | Aurion | 10 mL | Ask for price |
BSA tracer Ultra Small |
|||
| 200.133 | Aurion | 5 mL | Ask for price |
Anionic tracer Ultra Small |
|||
| 200.022 | Aurion | 10 mL | Ask for price |
Anionic tracer Ultra Small |
|||
| 200.122 | Aurion | 5 mL | Ask for price |
Long-Term Cell Tracing Reagent CMAC (Blue) |
|||
| EGY0171 | EnoGene | 100µg | EUR 92 |
Long-Term Cell Tracing Reagent CMAC (Blue) |
|||
| EGY0172 | EnoGene | 5x100µg | EUR 340 |
Long-Term Cell Tracing Reagent CMAC (Blue) |
|||
| MBS8579546-01mg | MyBiosource | 0.1mg | EUR 185 |
Long-Term Cell Tracing Reagent CMAC (Blue) |
|||
| MBS8579546-5x01mg | MyBiosource | 5x0.1mg | EUR 420 |
Long-Term Cell Tracing Reagent CMFDA(Green) |
|||
| EGY0181 | EnoGene | 100µg | EUR 220 |
Long-Term Cell Tracing Reagent CMFDA(Green) |
|||
| EGY0182 | EnoGene | 5x100µg | EUR 500 |
Long-Term Cell Tracing Reagent CMFDA (Green) |
|||
| MBS8579547-01mg | MyBiosource | 0.1mg | EUR 300 |
Long-Term Cell Tracing Reagent CMFDA (Green) |
|||
| MBS8579547-5x01mg | MyBiosource | 5x0.1mg | EUR 580 |
Human EGF HRP Tracer Antibody |
|||
| MP190220T | Antigenix America | 0.2 mL | Ask for price |
BSA tracer Conventional 6-nm |
|||
| 206.033 | Aurion | 10 mL | Ask for price |
BSA tracer Conventional 6-nm |
|||
| 206.133 | Aurion | 5 mL | Ask for price |
BSA tracer Conventional 10-nm |
|||
| 210.033 | Aurion | 10 mL | Ask for price |
BSA tracer Conventional 10-nm |
|||
| 210.133 | Aurion | 5 mL | Ask for price |
BSA tracer Conventional 15-nm |
|||
| 215.033 | Aurion | 10 mL | Ask for price |
BSA tracer Conventional 15-nm |
|||
| 215.133 | Aurion | 5 mL | Ask for price |
BSA tracer Conventional 25-nm |
|||
| 225.033 | Aurion | 10 mL | Ask for price |
BSA tracer Conventional 25-nm |
|||
| 225.133 | Aurion | 5 mL | Ask for price |
Human EGF Biotin Tracer Antibody |
|||
| MP190220B | Antigenix America | 0.1 mg | Ask for price |
Anti-Human Prolactin HRP Tracer |
|||
| MP100555T | Antigenix America | 200 µL | Ask for price |
Human Alpha Fetoprotein HRP Tracer |
|||
| MP700120T | Antigenix America | 0.2 mL | Ask for price |
Anionic tracer Conventional 6-nm |
|||
| 206.022 | Aurion | 10 mL | Ask for price |
Anionic tracer Conventional 6-nm |
|||
| 206.122 | Aurion | 5 mL | Ask for price |
Anionic tracer Conventional 10-nm |
|||
| 210.022 | Aurion | 10 mL | Ask for price |
Anionic tracer Conventional 10-nm |
|||
| 210.122 | Aurion | 5 mL | Ask for price |
Anionic tracer Conventional 15-nm |
|||
| 215.022 | Aurion | 10 mL | Ask for price |
Anionic tracer Conventional 15-nm |
|||
| 215.122 | Aurion | 5 mL | Ask for price |
Anionic tracer Conventional 25-nm |
|||
| 225.022 | Aurion | 10 mL | Ask for price |
Anionic tracer Conventional 25-nm |
|||
| 225.122 | Aurion | 5 mL | Ask for price |
Anti-Human IL-8 HRP Tracer |
|||
| MP800120T | Antigenix America | 0.2 mL | Ask for price |
Long-Term Cell Tracing Reagent CDCFDA, SE (Green) |
|||
| EGY0161 | EnoGene | 100 µg | EUR 160 |
Long-Term Cell Tracing Reagent CDCFDA, SE (Green) |
|||
| EGY0162 | EnoGene | 5 x 100 µg | EUR 340 |
Long-Term Cell Tracing Reagent CDCFDA, SE (Green) |
|||
| MBS8579545-01mg | MyBiosource | 0.1mg | EUR 245 |
Long-Term Cell Tracing Reagent CDCFDA, SE (Green) |
|||
| MBS8579545-5x01mg | MyBiosource | 5x0.1mg | EUR 420 |
Anti-Human IL-16 HRP Tracer |
|||
| MP160160T | Antigenix America | 0.2 mL | Ask for price |
Anti-Human MCP-1 HRP Tracer |
|||
| MP800320T | Antigenix America | 0.2 mL | Ask for price |
Anti-Human MCP-3 HRP Tracer |
|||
| MP800333T | Antigenix America | 0.2 mL | Ask for price |
Anti-Human IL-8 Biotin Tracer |
|||
| MP800120B | Antigenix America | 0.1 mL | Ask for price |
IAA tracer (alkaline phospahatase conjugated) |
|||
| AS09-517 | Agrisera AB | 1000 assays | EUR 208 |
ABA tracer (alkaline phospahatase conjugated) |
|||
| AS10-726 | Agrisera AB | 1000 assays | EUR 230 |
Anti-Human IL-15 Tracer -Biotin |
|||
| MP150150T | Antigenix America | 0.1 mL | Ask for price |
Anti-Human IL-16 Biotin Tracer |
|||
| MP160160B | Antigenix America | 0.1 mL | Ask for price |
Anti-Human IL-18 Tracer -Biotin |
|||
| MP180180T | Antigenix America | 0.1 mL | Ask for price |
Human GM-CSF HRP Tracer Antibody |
|||
| MP620120T | Antigenix America | 0.2 mL | Ask for price |
Human CRP HRP (poly) Tracer Antibody |
|||
| MP730730T | Antigenix America | 0.2 mL | Ask for price |
Anti-Human MCP-1 Biotin Tracer |
|||
| MP800320B | Antigenix America | 0.1 mg | Ask for price |
Anti-Human MCP-3 Biotin Tracer |
|||
| MP800333B | Antigenix America | 0.1 mg | Ask for price |
Anti-Human TNF Alpha Biotin Tracer |
|||
| MP500500B | Antigenix America | 0.5 mg | Ask for price |
Anti-Human Serum Amyloid HRP Tracer |
|||
| MP600200T | Antigenix America | 0.2 mL | Ask for price |
Human GM-CSF Biotin Tracer Antibody |
|||
| MP620120B | Antigenix America | 0.1 mg | Ask for price |
Human Growth Hormone HRP Tracer Antibody |
|||
| MP100222T | Antigenix America | 0.2 mL | Ask for price |
Anti-Human Serum Amyloid Biotin Tracer |
|||
| MP600200B | Antigenix America | 0.1 mL | Ask for price |
NIR-FLIVO 690 Tracer In vivo Assay |
|||
| MBS258410-20Tests | MyBiosource | 20Tests | EUR 535 |
NIR-FLIVO 690 Tracer In vivo Assay |
|||
| MBS258410-5x20Tests | MyBiosource | 5x20Tests | EUR 2460 |
NIR-FLIVO 747 Tracer In vivo Assay |
|||
| MBS258412-20Tests | MyBiosource | 20Tests | EUR 535 |
NIR-FLIVO 747 Tracer In vivo Assay |
|||
| MBS258412-5x20Tests | MyBiosource | 5x20Tests | EUR 2460 |
Human Growth Hormone Biotin Tracer Antibody |
|||
| MP100222B | Antigenix America | 0.1 mg | Ask for price |
Human Carcinoembryonic Antigen (CEA) HRP Tracer |
|||
| MP720720T | Antigenix America | 0.2 mL | Ask for price |
NIR-FLIVO® 690 Tracer In vivo Assay |
|||
| 9112 | Immunochemistry | 20 Tests | EUR 438 |
NIR-FLIVO® 747 Tracer In vivo Assay |
|||
| 9114 | Immunochemistry | 20 Tests | EUR 438 |
Cis-zeatin tracer (alkaline phospahatase conjugated) |
|||
| AS16-4092 | Agrisera AB | 1000 assays | EUR 230 |
Trans-zeatin tracer (alkaline phospahatase conjugated) |
|||
| AS16-4090 | Agrisera AB | 1000 assays | EUR 230 |
CytoSelect™ Cell Transformation Assay (Cell Recovery Compatible), Colorimetric |
|||
| CBA-135 | Cell Biolabs | 96 assays | EUR 596 |
CytoSelect™ Cell Transformation Assay (Cell Recovery Compatible), Colorimetric |
|||
| CBA-135-5 | Cell Biolabs | 5 x 96 assays | EUR 2592 |
CytoSelect™ Cell Transformation Assay (Cell Recovery Compatible), Fluorometric |
|||
| CBA-140 | Cell Biolabs | 96 assays | EUR 624 |
CytoSelect™ Cell Transformation Assay (Cell Recovery Compatible), Fluorometric |
|||
| CBA-140-5 | Cell Biolabs | 5 x 96 assays | EUR 2700 |
Anti-Human Prostate Specific Antigen HRP Tracer |
|||
| MP100444T | Antigenix America | 0.4 mL | Ask for price |
Anti-Human Prostate Specific Antigen Biotin Tracer |
|||
| MP100444B | Antigenix America | 0.1 mg | Ask for price |
CytoSelect Cell Transformation Assay (Cell Recovery Compatible), Colorimetric, Trial Size |
|||
| CBA-135-T | Cell Biolabs | 24 assays | EUR 518.4 |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
|||
N6-isopentenyladenosine tracer (alkaline phospahatase conjugated) |
|||
| AS17-4132 | Agrisera AB | 1000 assays | EUR 208 |
HRP conjugated mAb anti-Human TNF-alpha (Tracer) |
|||
| MBS592166-02mL | MyBiosource | 0.2mL | EUR 580 |
HRP conjugated mAb anti-Human TNF-alpha (Tracer) |
|||
| MBS592166-5x02mL | MyBiosource | 5x0.2mL | EUR 2355 |
Anti-Human Beta Amyloid Peptide 42- BIOTIN TRACER |
|||
| NS22020B | Antigenix America | 0.1 mL | Ask for price |
CytoSelect 96-Well Cell Transformation Assay (Cell Recovery Compatible, Fluorometric), Trial Size |
|||
| CBA-140-T | Cell Biolabs | 24 assays | EUR 547.2 |
|
Description: CytoSelect 96-Well Cell Transformation Assays (Cell Recovery Compatible) provide a robust system for detecting transformed cells, screening cell transformation inhibitors, and determining in vitro drug sensitivity. A proprietary modified soft agar matrix allows you to either quantify cells using the included fluorescent dye, or recover the cells for further analysis. |
|||
Anti-Human CA 19-9 Tumor Marker - HRP Tracer |
|||
| MP19920T | Antigenix America | 200 µL | Ask for price |
154 patients from Pedi CART19, ELIANA, ENSIGN, and 16CT022 received tisagenlecleucel and 41 patients from the 13BT022 trial received the humanised CD19-directed CAR, huCART19. We categorised patients into two strata on the basis of CNS status at relapse or within the 12 months preceding CAR T-cell infusion-either CNS-positive or CNS-negative disease. Patients with CNS-positive disease were further divided on the basis of morphological bone marrow involvement-either combined bone marrow and CNS involvement, or isolated CNS involvement.
